MOLDTKPAC Mold-Tek Packaging Q4 FY25 results (Jan–Mar 2025) and concall
Mold-Tek Packaging closed FY25 with an 11.8% sales growth and 7.3% volume growth, despite a 9% PAT decline due to higher depreciation and financial costs. A significant highlight was the Pharma division achieving break-even in Q4, with turnover tripling from Q3 to Q4. The company also saw a positive turnaround in the paint industry, moving from a decline to 6.8% growth, and strong 25% growth in Food and FMCG in Q4, driven by improved printing capacity. Management is optimistic about FY26, targeting double-digit growth across segments and improved EBITDA margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 191 | 191 | 203 |
| EBITDA | 34 | 34 | 38 |
| Net profit | 14 | 14 | 16 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
